Cryoport up in Q1, continues to ride CAR T-cell wave
Novartis’ second US FDA-approved indication for Kymriah will help “fuel topline growth” says the logistics firm.
Archives for May 8, 2018
Recoding the human genome: Cellectis, Wyss aim to construct virus-resistant cells
Researchers at the Wyss Institute are teaming up with Cellectis to develop “ultra-safe” human cells resistant to infection – which could enable more effective ways to manufacture protein therapeutics, vaccines, and cell therapies.
Novartis wins second US FDA approval for Kymriah, $100k cheaper
Novartis has scored a second US FDA approval for CAR T-cell therapy Kymriah, indicated to treat adult patients with relapsed or refractory (r/r) large B-cell lymphoma.
GE launches temperature controlled processing tech for CAR T-cell therapy
GE Healthcare Life Sciences has launched an updated, flexible cell processing system designed to rapidly and effectively harvest cells for treatments, including CAR T-cell therapy.